This study determined if altered vascular prostacyclin (PGI 2 ) and/or thromboxane (TxA 2 ) production with reduced PO 2 contributes to impaired hypoxic dilation of skeletal muscle resistance arterioles of obese Zucker rats (OZR) vs. lean Zucker rats (LZR). Mechanical responses were assessed in isolated gracilis muscle arterioles following reductions in PO 2 under control conditions and following pharmacological interventions inhibiting arachidonic acid metabolism, nitric oxide synthase, and alleviating elevated vascular oxidant stress.
INTRODUCTION
The metabolic syndrome represents a series of systemic pathologies that develop sequentially in afflicted individuals, and can include obesity, insulin resistance/type II diabetes mellitus, dyslipidemia and hypertension (25) .
While each of these pathologies in isolation can increase the future risk for development of peripheral vascular disease, when present in combination this risk increases dramatically (24) , and can lead to numerous profound alterations to vascular structure/function relationships (26, 27) . These vascular alterations can impair to tissue perfusion:demand matching and can lead to a compromised function (27) . An effective animal model for the metabolic syndrome in humans is the obese Zucker rat (OZR), a rodent model characterized by its dysfunctional leptin receptor gene, resulting in abrogated leptin signaling and an impaired satiety reflex (10) . As a result, the OZR experiences a chronic hyperphagia, and sequentially develops each of the systemic pathologies listed above, in addition to both pro-oxidant and pro-inflammatory states (1, 6, 22) . Previous studies by multiple investigative groups have demonstrated negative vascular outcomes in OZR with development of the metabolic syndrome, including alterations to vascular wall mechanics (4, 13, 28, 29) , impairments to multiple indices of dilator reactivity (9, 13, 15, 16, 33) , signaling mechanisms underlying constrictor reactivity (17, 21, 30 ) and a rarefaction of microvascular networks within multiple tissues (7, 8, 31) . The culmination of these alterations to microvascular structure and function within OZR can result in profound impairments to the perfusion of tissue under an array of physiological and pathological conditions (8, 12, 33) .
We have previously demonstrated that the dilator reactivity of skeletal muscle resistance arterioles in response to an acute reduction in oxygen tension is impaired in OZR compared to LZR, and that a contributing mechanism to this impairment lies within the chronic elevation in vascular oxidant stress (9) . However, while this previous study did not implicate specific mechanisms beyond the contribution of elevated vascular oxidant stress, recent studies from Hester's group have provided data which may have considerable bearing on not only our previous observation, but also on the integrated regulation of vascular reactivity in the skeletal muscle of OZR (32, 33) . Specifically, the dilator response of in situ spinotrapezius muscle arterioles with increased metabolic demand, previously determined to be a largely dependent on vascular production of prostacyclin (PGI 2 , Ref. 11), was blunted H-00596-2008 4 in OZR compared to LZR. This observation may reflect an enhanced vascular production of thromboxane A 2 (TxA 2 ), or elevated vasoconstrictor response to TxA 2 within OZR that is not present in lean animals (32, 33) .
Clearly, any increase in TxA 2 production has the potential to compete against PGI 2 -mediated responses and impair dilator reactivity to multiple vasoactive stimuli.
The purpose of the present study was to more fully elucidate mechanisms contributing to the impaired dilation of skeletal muscle arterioles of OZR in response to reduced PO 2 . Additionally, the present study was designed to more clearly determine the role for elevated vascular oxidant stress in contributing to the attenuated hypoxic dilation of arterioles from OZR. Specifically, the hypothesis tested by the present experiments was that the compromised dilator reactivity of skeletal muscle arterioles of OZR in response to reduced PO 2 compared to responses in LZR is due to a reduction in the vascular production of PGI 2 and an increased vascular production of TxA 2 as a result of the acute reductions in oxygen tension. Further, these effects on PGI 2 and TxA 2 production will be the result of an elevation in vascular oxidant stress, altering arachidonic acid metabolism within arterioles of OZR. chamber (37°C) that allowed the vessel lumen and exterior to be perfused and superfused, respectively, with physiological salt solution (PSS; equilibrated with 21% O 2 , 5% CO 2 ; 74% N 2 ) from separate reservoirs. Vessels were cannulated at both ends and were secured to inflow and outflow glass micropipettes connected to a reservoir perfusion system allowing intralumenal pressure and gas concentrations to be controlled. Arterioles were extended to their in situ length and were equilibrated at 80% of the animal's mean arterial pressure (Table   1 ). Vessel diameter was measured using television microscopy and an on-screen video micrometer, and all mechanical responses of arterioles were assessed under pressurized conditions with no flow through the arteriolar lumen.
MATERIALS AND METHODS

Animals
Subsequent to the initial equilibration period, the reactivity of isolated arterioles was assessed following Data are presented as mean±SEM. Statistically significant differences in the magnitude of hypoxic dilation, vascular production of 6-keto-PGF 1α and 11-dehydro-TxB 2 , and the calculated parameters describing the thromboxane or prostacyclin concentration-response relationships were determined using analysis of variance (ANOVA). In all cases, Student-Newman-Keuls post hoc test was used when appropriate and p<0.05 was taken to reflect statistical significance. Table 1 presents baseline characteristics of LZR and OZR in the present study. At 15-17 weeks of age, OZR demonstrated profound obesity, severe insulin resistance, and dyslipidemia characterized by moderate hypercholesterolemia and severe hypertriglyceridemia. In addition, OZR also presented a moderate elevation in mean arterial pressure as compared to LZR. Plasma levels of nitrotyrosine, a protein marker of chronic elevations in oxidant stress, were significantly elevated in OZR compared to LZR. With regard to basal vascular tone, isolated arterioles from both rat strains demonstrated a comparable resting active diameter, although passive diameter was reduced in OZR versus LZR. However, this remodeling of the vessel wall did not translate into a difference in calculated active tone between the strains.
RESULTS
Data summarizing hypoxic dilation of resistance arterioles from LZR and OZR are presented in Figure 1 .
As shown in Panel A, arterioles from OZR exhibited a blunted dilator response to reduced PO 2 compared to vessels from LZR. However, arteriolar reactivity to reduced oxygen tension was abolished in both groups following removal of the vascular endothelium. Panel B presents data describing the contribution of nitric oxide synthase (NOS) and cyclooxygenase (COX) products to arteriolar dilation in response to reduced PO 2 in LZR and OZR.
While NOS inhibition has a consistently minor, albeit statistically insignificant, blunting of hypoxic dilation in arterioles of LZR, treatment of vessels with L-NAME had no discernible impact on this response in OZR. In contrast, incubation of vessels with indomethacin dramatically reduced hypoxic dilation in arterioles from both strains. Combined treatment with L-NAME and indomethacin abolished all vascular responses to reduced PO 2 in both LZR and OZR. Panel C presents the impact of pre-treatment of arterioles with the anti-oxidant PEG-SOD on both the magnitude of hypoxic dilation in these vessels and on the contributions from NOS and COX. Treatment of vessels with PEG-SOD had no significant impact on either the magnitude of hypoxic dilation or on the contribution of NOS and COX products to this response in LZR. In contrast, following incubation with PEG-SOD, arterioles from OZR exhibited an improved dilation in response to reduced PO 2 , and this enhanced reactivity was entirely dependent on COX metabolism. Figure 2 presents data describing the production of 6-keto-PGF 1α (the stable breakdown product of PGI 2 ) and 11-dehydro-TxB 2 (the stable breakdown product of TxA 2 ) from pooled vessels of LZR and OZR in response to
production in response to reduced PO 2 , although this increase was greater in LZR as compared to OZR. In both cases, treatment of vessels with indomethacin abolished 6-keto-PGF 1α production in response to reduced oxygen tension. With regard to the vascular production of TxA 2 , vessels from both LZR and OZR exhibited a significant increase in 11-dehydro-TxB 2 production following exposure to reduced PO 2 , although this level of production was dramatically elevated in vessels from OZR (Panel B). In both cases, production of 11-dehydroTxB 2 was abolished following treatment of vessels with either indomethacin or CHI, suggesting that all production of TxA 2 was mediated via the actions of thromboxane synthase distal to COX.
Data describing the production of 6-keto-PGF 1α and 11-dehydro-TxB 2 in response to reduced PO 2 in vessels from OZR subsequent to pre-treatment with PEG-SOD are summarized in Figure 3 . Treatment of vessels with PEG-SOD did not alter 6-keto-PGF 1α production in vessels from OZR compared to levels in untreated vessels 
DISCUSSION
Inherent within the development of the multi-pathology state that defines the metabolic syndrome is an array of alterations to vascular and microvascular structure and function that have the potential to profoundly impact the perfusion of tissues and organs, as well as the contributing mechanisms which comprise this integrated process.
Previous studies have clearly demonstrated that alterations to the patterns of vasodilator (8, 12) and vasoconstrictor (30) reactivity, as well as vessel wall remodeling (28, 29) and a reduction in microvessel density (7) all represent avenues through which vascular function and tissue perfusion can be compromised. The purpose of the present study was to build on our previous observation of an impaired dilation of skeletal muscle resistance arterioles of OZR in response to acute reductions in oxygen tension, and the possible contributing role of elevated vascular oxidant stress in this process (9) .
Comparable to our observations in the first study, hypoxic dilation of skeletal muscle resistance arterioles from OZR was significantly reduced compared to that determined in LZR (Figure 1, Panel A) . While this response was abolished following removal of the endothelium in both rat strains, comparable to the complete endotheliumdependence of hypoxic dilation in other rodent models (14, 19, 20) , our results also support previous observations of a strong dependence on COX products in mediating hypoxic dilation of these vessels (18) (19) (20) . Interestingly, in our initial study we determined a small, but significant role for NOS activity in mediating hypoxic dilation in arterioles from LZR. In the present study this effect was not statistically significant, suggesting that it may represent a minor contributor to arteriolar dilation in response to reduced oxygen tension in LZR. However, while the magnitude of this response is relatively minor in LZR, both the results from the present study and our previous one (9) indicate that this is completely lost with the development of the metabolic syndrome in OZR. Additionally, pre-treatment of arterioles from OZR with the oxidative free radical scavenger PEG-SOD to lower the elevated oxidant stress in these animals resulted in a significant improvement to hypoxic dilation in the obese rats (Figure 1, Panel C) . This improvement to hypoxic dilation was confined to activity involving COX only, as treatment with indomethacin abolished hypoxic dilation in OZR, and treatment with L-NAME was without effect.
Recent studies from Hester's group suggest that functional dilation (i.e., arteriolar dilation in response to elevated metabolic demand) is impaired in OZR as a result of alterations to arachidonic acid metabolism which can result in activation of thromboxane receptors causing a competing constrictor influence which acts to partially constrain dilator responses (32, 33) . Given that both functional dilation for in situ spintotrapezius muscle of LZR (11) and hypoxic dilation of skeletal muscle arterioles of LZR (9) has previously been shown to be strongly dependent on the vascular production of PGI 2 , we sought to determine if an alteration in arachidonic acid metabolism, resulting in an increased vascular production of thromboxane or a decreased production of prostacyclin may contribute to this impaired reactivity in arterioles of OZR. As shown in Figure 2 , arteries from OZR exhibited a significant increase in the production of PGI 2 (estimated from measurements of 6-keto-PGF 1α ) in response to reductions in oxygen tension. While this was not as robust a response as that determined for arteries of LZR, it is unclear if this degree of attenuation in PGI 2 production in OZR is sufficient to manifest itself as a blunted mechanical response. In contrast, vascular production of TxA 2 (estimated from measurements of 11-dehydroTxB 2 ), mildly elevated in arteries of LZR during reduced oxygen tension, was dramatically increased in vessels from OZR following exposure to reduced PO 2 . Finally, while treatment of arteries from both strains with indomethacin abolished production of PGI 2 and TxA 2 in response to reduced oxygen tension, the treatment of vessels of OZR with CHI, an inhibitor of thromboxane synthase, severely reduced thromboxane production in vessels from OZR ( Figure 2, Panel B) . These results suggest that reduced PO 2 causes an increased production of TxA 2 from vessels of OZR, mediated via thromboxane synthase, and that this may compete with the dilator influences of vascular production of PGI 2 . However, it should be emphasized that these results must be interpreted cautiously, as the production of metabolites of arachidonic acid was assessed using conduit arteries and not resistance arterioles, while the reverse is true with regard to the study of the mechanical responses.
In order to better understand the impact of elevated vascular oxidant stress on the impaired dilator responses to reduced PO 2 in vessels of OZR, we treated vessels with PEG-SOD prior to exposure to reduced PO 2 and H-00596-2008 11 determined the levels of 6-keto-PGF 1α and 11-dehydro-TxB 2 in the incubation superfusate (Figure 3) . These data suggest that while oxidant stress does not play a significant role in any reduction in the vascular production of prostacyclin (as the addition of PEG-SOD was without effect), elevated vascular oxidant stress may contribute to the increased production of thromboxane by these vessels, as incubation with the anti-oxidant significantly reduced the levels of 11-dehydro-TxB 2 in the superfusate. However, this effect was not complete, as the levels of 11-dehydro-TxB 2 production remained elevated in the superfusate despite the presence of PEG-SOD, indicating that additional factors may contribute to thromboxane production in vessels of OZR which are independent of the effects of acute reduction in vascular oxidant stress. This observation of a role for oxidant stress in shifting arachidonic acid metabolism toward an increased production of thromboxane has been identified previously (2, 3, 34) , and the results of the present study suggest that a comparable effect may be occurring in the vasculature of OZR, with the net result of a blunted vascular response to stimuli that are dependent on PGI 2 production for their full manifestation.
To better evaluate this statement, isolated skeletal muscle resistance arterioles from LZR and OZR were exposed to acute reductions in oxygen tension under control conditions and in response to either PGH 2 /TxA 2 receptor blockade with SQ-29548 or thromboxane synthase inhibition with CHI ( Figure 4 ). Although these pharmacological challenges had no consistent impact on hypoxic dilation in arterioles from LZR, both interventions resulted in improved dilator reactivity in response to reduced PO 2 in arterioles of OZR. Taken with the previous results, these data clearly suggest that an increased production of TxA 2 contributes to the impaired hypoxic dilation in arterioles of OZR. However, the data presented in Figure 4 do not allow for discrimination between increased vascular production of TxA 2 , an increased vascular sensitivity to produced TxA 2 , or an altered vascular sensitivity to produced PGI 2 .
In order to assess this final issue, isolated arterioles from both rat strains were challenged with increasing concentrations of thromboxane or prostacyclin ( Figure 5 ). Vasoconstrictor reactivity to thromboxane was very similar between arterioles of LZR and OZR, and in both cases constrictor responses to thromboxane were largely independent of oxidant stress (i.e., no identifiable impact of treatment with PEG-SOD) and were abolished by H-00596-2008 12 blockade of the PGH 2 /TxA 2 receptor. These observations suggest that the vascular sensitivity to thromboxane is not significantly impacted by the presence of the metabolic syndrome. In contrast, vascular reactivity to prostacyclin was significantly reduced in arterioles of OZR and this impairment was blunted following a reduction in oxidant stress with PEG-SOD. Whether this impaired response to PGI 2 represents oxidant radical degradation of prostacyclin (leading to the production of isoprostanes), altered function at the level of the prostacyclin receptor, the impact of elevated oxidant stress on the intracellular signaling cascade distal to the receptor, or a combination of these effects remains to be determined.
In summary, with the evolution of the metabolic syndrome in obese Zucker rats, the dilator responses of skeletal muscle resistance arterioles following acute reductions in oxygen tension are significantly attenuated. Both biochemical and pharmacological evidence suggests that this impaired dilator reactivity may be the result of an increase in vascular production of thromboxane with reduced PO 2 which could represent a constrictor influence which competes against the dilator effects of prostacyclin (the production of which appears to be largely intact).
Normalizing vascular oxidant stress blunts the increased reduced PO 2 -induced production of thromboxane in vessels from OZR and also increases the responsiveness of arterioles of OZR to exogenously supplied prostacyclin, thus leading to an improvement in the mechanical response of the vessel to reduced oxygen tension. The present study provides no compelling evidence that skeletal muscle arteriolar sensitivity to thromboxane is altered with the progression of the metabolic syndrome. 
